{"id":411875,"date":"2021-01-11T08:03:23","date_gmt":"2021-01-11T13:03:23","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=411875"},"modified":"2021-01-11T08:03:23","modified_gmt":"2021-01-11T13:03:23","slug":"spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","title":{"rendered":"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">TORONTO, Jan.  11, 2021  (GLOBE NEWSWIRE) &#8212; <strong>Spectral Medical Inc.<\/strong><strong> (\u201cSpectral\u201d or the \u201cCompany\u201d) (TSX: EDT),<\/strong> a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (\u201cDialco\u201d), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference, being held January 11 \u2013 14, 2021.\u00a0Dr. Paul Walker, President and CEO, and Chris Seto, COO and CFO of Spectral Medical Inc. will be hosting the presentation.<\/p>\n<p>\n        <strong>About Spectral<\/strong>\n      <\/p>\n<p>Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin\u2122 (\u201cPMX\u201d). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company\u2019s Endotoxin Activity Assay (EAA\u2122), the only FDA cleared diagnostic for the risk of developing sepsis.<\/p>\n<p>PMX is approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 200,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. Approximately 330,000 patients are diagnosed with severe sepsis and septic shock in North America each year.<\/p>\n<p>Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new proprietary platform, \u201cSAMI\u201d, targeting the renal replacement therapy (\u201cRRT\u201d) market.\u00a0 Dialco is also seeking regulatory approval for in-home use of \u201cDIMI\u201d which is based on the same RRT platform, but will be intended for home hemodialysis use.\u00a0 \u201cDIMI\u201d recently received its FDA 510k clearance for use in hospital and clinical settings.<\/p>\n<p>Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NriprrzyNqCUZa6Lw-fvPGwefG-V0tPyWAGmI6nSYV_LLqcI57y-NtGtRko_MWpZ9FnaHtv5jnkVmrNq2LH65w1Lt_WLn3mm5n-Nn0r6I2s=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.spectraldx.com<\/a>.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:36%;width:36%;min-width:36%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong>Contact:<br \/><\/strong>Dr. Paul Walker\u00a0<br \/>President and CEO\u00a0<br \/>Spectral Medical Inc.<br \/>416-626-3233 ext. 2100\u00a0<br \/><a href=\"mailto:pwalker@spectraldx.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>pwalker@spectraldx.com<\/u><\/a><\/td>\n<td style=\"max-width:32%;width:32%;min-width:32%;text-align: left;vertical-align: middle;vertical-align: bottom\">Mr. Chris Seto\u00a0<br \/>COO &amp; CFO\u00a0<br \/>Spectral Medical Inc.<br \/>416-626-3233 ext. 2004\u00a0<br \/><a href=\"mailto:cseto@spectraldx.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>cseto@spectraldx.com<\/u><\/a>\u00a0<\/td>\n<td style=\"max-width:32%;width:32%;min-width:32%;text-align: left;vertical-align: middle;vertical-align: bottom\">Ali Mahdavi<br \/>Capital Markets &amp; Investor<br \/>Relations<br \/>416-962-3300<br \/><a href=\"mailto:am@spinnakercmi.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>am@spinnakercmi.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">David Waldman\/Natalya Rudman<br \/>US Investor Relations<br \/>Crescendo Communications, LLC<br \/><u>212-671-1020<\/u><br \/><a href=\"mailto:edt@crescendo-ir.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">edt@crescendo-ir.com<\/a><\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3154c0aa-6ee2-4b3b-96b3-87ad0f6780bd\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TORONTO, Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Spectral Medical Inc. (\u201cSpectral\u201d or the \u201cCompany\u201d) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (\u201cDialco\u201d), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference, being held January 11 \u2013 14, 2021.\u00a0Dr. Paul Walker, President and CEO, and Chris Seto, COO and CFO of Spectral Medical Inc. will be hosting the presentation. About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin\u2122 (\u201cPMX\u201d). PMX is &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-411875","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TORONTO, Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Spectral Medical Inc. (\u201cSpectral\u201d or the \u201cCompany\u201d) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (\u201cDialco\u201d), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference, being held January 11 \u2013 14, 2021.\u00a0Dr. Paul Walker, President and CEO, and Chris Seto, COO and CFO of Spectral Medical Inc. will be hosting the presentation. About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin\u2122 (\u201cPMX\u201d). PMX is &hellip; Continue reading &quot;Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-11T13:03:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference\",\"datePublished\":\"2021-01-11T13:03:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"},\"wordCount\":371,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\",\"name\":\"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=\",\"datePublished\":\"2021-01-11T13:03:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_locale":"en_US","og_type":"article","og_title":"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","og_description":"TORONTO, Jan. 11, 2021 (GLOBE NEWSWIRE) &#8212; Spectral Medical Inc. (\u201cSpectral\u201d or the \u201cCompany\u201d) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (\u201cDialco\u201d), today announced that it will be presenting at the H.C. Wainwright Virtual BioConnect Conference, being held January 11 \u2013 14, 2021.\u00a0Dr. Paul Walker, President and CEO, and Chris Seto, COO and CFO of Spectral Medical Inc. will be hosting the presentation. About Spectral Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin\u2122 (\u201cPMX\u201d). PMX is &hellip; Continue reading \"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-11T13:03:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference","datePublished":"2021-01-11T13:03:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"},"wordCount":371,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/","name":"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=","datePublished":"2021-01-11T13:03:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMzAyMSMzOTExMDg0IzIwOTQ5NTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectral-medical-to-present-at-the-h-c-wainwright-virtual-bioconnect-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spectral Medical to Present at the H.C. Wainwright Virtual BioConnect Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411875","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=411875"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/411875\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=411875"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=411875"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=411875"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}